Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolios

Broadwood Partners buys Oncocyte shares worth $7.06m

Published 04/15/2024, 07:24 PM

In a recent transaction, Broadwood Partners, L.P., a significant shareholder in Oncocyte Corp (NYSEAMERICAN:OCX), has increased its investment in the company. The investment firm purchased 2,420,000 shares of the diagnostics company's common stock at a price of $2.9164 per share, amounting to a total investment of approximately $7.06 million.

This purchase, executed on April 11, 2024, reflects a strong signal of confidence in Oncocyte by Broadwood Partners, which, through its related entities, holds a substantial stake in the company. Broadwood Partners is known to be a ten-percent owner of Oncocyte, indicating their significant influence and interest in the firm's success.

Additionally, on April 15, 2024, Oncocyte redeemed all shares of its Series A Convertible Preferred Stock previously owned by Broadwood Partners. The mandatory redemption was part of the terms agreed upon in the Securities Purchase Agreement. Broadwood Partners received a total of $3,289,144.18 from the redemption, which translates to $1,118.30902 per share of the Series A Convertible Preferred Stock. This transaction showcases the liquidity event for Broadwood Partners and the ongoing financial maneuvers associated with their investment in Oncocyte.

The recent transactions underline the dynamic nature of Broadwood Partners' involvement with Oncocyte and the investment firm's role as a key stakeholder. Investors and market watchers often scrutinize such moves by major shareholders, as they can be indicative of the company's future prospects and the confidence that significant investors have in its management and growth trajectory.

Oncocyte Corp, which specializes in in vitro and in vivo diagnostic substances, has a diverse portfolio of diagnostic tests and continues to make strides in the biotechnology industry. The company's business address is located in Irvine, California.

3rd party Ad. Not an offer or recommendation by See disclosure here or remove ads .

All details of these transactions are publicly documented in accordance with SEC regulations, and the calculated total values provided are based on the latest available information.

InvestingPro Insights

Oncocyte Corp (NYSEAMERICAN:OCX) has been under the spotlight with Broadwood Partners, L.P. increasing its stake, signifying a potential bullish outlook from the investment firm. In the context of this development, certain key metrics from InvestingPro provide a mixed financial perspective on the company.

InvestingPro Data reveals a market capitalization of approximately $20.9 million USD, which places Oncocyte in the small-cap category, often associated with higher growth potential but also higher risk. Additionally, a revenue growth of 216.48% in the last twelve months as of Q3 2023 indicates a significant increase in sales, a positive sign for potential investors. However, the operating income margin for the same period stands at -1586.94%, reflecting substantial operational costs relative to the revenue.

Among the InvestingPro Tips, two are particularly noteworthy in light of the recent transactions. Firstly, Oncocyte is identified as holding more cash than debt on its balance sheet, which could provide a cushion for operational flexibility. Secondly, analysts do not anticipate the company will be profitable this year, which may temper expectations for short-term earnings growth.

For investors seeking a deeper dive into Oncocyte's financial health and future prospects, InvestingPro offers additional insights. There are currently 5 more InvestingPro Tips available, which can provide a comprehensive understanding of the company's financial position and market potential. Interested readers can access these valuable tips by visiting and using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

3rd party Ad. Not an offer or recommendation by See disclosure here or remove ads .

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.